FDA Upgrades Recall on 54,000 Bottles of Common Thyroid Medication

The agency said in a notice that the recall was initiated due to sub-potency problems.

The sign outside the U.S. Food and Drug Administration's (FDA) White Oak campus in Silver Spring, Md., on July 17, 2025. Issam Ahmed/AFP via Getty Images

The Food and Drug Administration upgraded the recall of a type of commonly used thyroid medication due to low potency issues, according to a notice posted by the agency.

The agency said that 54,432 bottles of levothyroxine sodium tablets are being recalled because of sub-potency and upgraded the recall to Class II on Oct. 6. The prescription-only tablets come in 88 mcg, or 0.088 milligram, amounts at 90 tablets per bottle, the notice said.